Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32680077 | 0.90 | MAPT (0.50) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL8067762 | 0.90 | MAPT (0.50) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL4019694 | 0.86 | SMYD3 (0.58) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL444953 | 0.84 | GAA (0.69) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL29831598 | 0.84 | GAA (0.69) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL1150614 | 0.84 | GAA (0.69) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL1531662 | 0.84 | GAA (0.69) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL3120548 | 0.83 | SMYD3 (0.56) | SMYD3MAPTGAAMTNR1AF2 | |
| Hydrochloric Acid SCHEMBL11050093 | 0.83 | GAA (0.67) | SMYD3MAPTGAAMTNR1AF2 | |
| SCHEMBL6206546 | 0.83 | SMYD3 (0.56) | SMYD3MAPTGAAMTNR1AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| EP-3191476-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Limited (GB) | 2017-07-19 | — | — | EP | claimed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | claimed |
| WO-2016038120-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-03-17 | — | — | WO | claimed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | claimed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | claimed |
| EP-2582676-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2011159554-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | claimed |
| EP-2234485-A1 | STABLE LAQUINIMOD PREPARATIONS | Teva Pharmaceutical Industries Ltd. (IL) | 2010-10-06 | — | — | EP | claimed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | claimed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2009082471-A1 | STABLE LAQUINIMOD PREPARATIONS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-07-02 | — | — | WO | claimed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| CN-119866217-A | Agent for restoring metal steady state containing malonic acid or derivative thereof | 牛津抗生素(制药)集团股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-1070054-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052875-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | SMYD3 1909/4885MAPT 4324/4885GAA 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.